OBD signs a major contract with the University of Glasgow.

Oxford Biodynamics has signed a major contract with the University of Glasgow to develop epigenetic deregulation know how and biomarkers to be used to differentiate between RA patients, healthy controls and responders/non-responders to methotrexate (MTX).